Cerity Partners’s Matinas BioPharma MTNB Stock Holding History

Cerity Partners’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,460	Closed	-$95K	–	712
2021 Q2	$95K	Hold	2,460	–	–	﹤0.01%	698
2021 Q1	$129K	Buy	+2,460	New	+$165K	﹤0.01%	677

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cerity Partners's MTNB Position: Q3 2021 in Review

Cerity Partners sold out of Matinas BioPharma (MTNB) in Q3 2021, closing a stake of 2,460 shares — an estimated $95K sold.

Cerity Partners first reported a position in MTNB in Q1 2021 and held it in 2 quarters. The position peaked at $129K in Q1 2021. 67 funds tracked by Wall St. Rank hold MTNB as of Q3 2021.

Cerity Partners reported no remaining Matinas BioPharma position as of Q3 2021 after selling out during the quarter.
Cerity Partners sold 2,460 Matinas BioPharma shares in Q3 2021, an estimated $95K.
Cerity Partners first reported a position in Matinas BioPharma in Q1 2021 and held it in 2 quarters.
Cerity Partners's Matinas BioPharma position peaked at $129K in Q1 2021.
67 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2021.

Based on Cerity Partners's 13F filing for Q3 2021, filed 25 Oct 2021.